{
    "nct_id": "NCT06588413",
    "official_title": "Randomized, Double-Blind Study of FOND (Fosaprepitant, ONdansetron, Dexamethasone) Plus Either Olanzapine 2.5 mg Versus 5 mg for the Prevention of Chemotherapy Induced Nausea and Vomiting in Patients Receiving High-dose Melphalan Conditioning: The FONDO-LOW Study",
    "inclusion_criteria": "* Receipt of high-dose melphalan 140-200 mg/m2\n* Autologous stem cell transplantation recipient\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Allergy to olanzapine\n* Documented nausea or vomiting within 24 hours prior to enrollment\n* Treatment with other antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone within 30 days prior to enrollment or planned during protocol therapy\n* Chronic alcoholism\n* Pregnant\n* Decline or unable to provide informed consent",
    "miscellaneous_criteria": ""
}